Chemotherapy plus immunotherapy before surgery for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of chemotherapy and an immunotherapy drug before surgery helps shrink stomach cancer tumors and improve outcomes. The treatment is given in the neoadjuvant (before surgery) setting for stomach cancer that is locally advanced but not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stomach cancer that has not spread to distant organs.
- You have not received any prior chemotherapy, radiation, targeted therapy, or immunotherapy for this cancer.
- You have a tumor that can be measured on a CT or MRI scan.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- Your heart, liver, kidney, and blood counts meet the study's safety checks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four drugs that are given before surgery for stomach cancer. The goal is to shrink the tumor and make it easier to remove, with the hope of improving long-term outcomes.
This trial tests whether adding an immunotherapy drug (sintilimab) to two different chemotherapy combinations before surgery can help shrink stomach cancer and improve outcomes. It is for people with locally advanced stomach cancer that can be removed with surgery.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
This trial tests giving an immunotherapy drug before surgery to see if it can increase immune cells in the tumor and improve outcomes for people with advanced stomach cancer. It may help shrink the tumor and make surgery more effective.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
Hear when a new Locally Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.